Released Nov 14, 2012, during market hours
10-Q filed Nov 14, 2012, 45 days after period end · 0001213900-12-006126
Q3 2012 · 10-Q
Revenue$9.91M$9.91M +58.6% vs Q3 2011+33.3% vs Q2 2012
Net Income$968.63K$968.63K N/M vs Q3 2011+255.6% vs Q2 2012
EPS Diluted$0.07$0.07 N/M vs Q3 2011+250.0% vs Q2 2012
Gross Profit$3,385,103+50.9%
Operating Income$2,182,489+81.3%
Operating Cash Flowderived$1,552,233+5,889.2%
Free Cash Flowderived$1,140,657N/M
Margins · derived
Gross margin34.2%−1.7 pt vs Q3 2011
Operating margin22.0%+2.8 pt vs Q3 2011
Net margin9.8%+32.9 pt vs Q3 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $9.91M | $6.25M | $5.70M |
| Net Income | $968.63K | -$1.45M | $760.16K |
| EPS Diluted | $0.07 | -$0.11 | $0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tanke Biosciences Corp · CIK 1452011 · Engraved from SEC EDGAR